title: Lack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft model.
abstract: Patients with metastatic neuroblastoma are rarely curable with currently available therapy, and the search for new treatment options, which include the use of inhibitors of tumor angiogenesis, is warranted. Here, we have evaluated the efficacy of one of the most promising natural inhibitors of angiogenesis described to date, endostatin, in a human neuroblastoma xenograft model in nude mice. Murine endostatin cDNA was cloned in a bacterial expression vector, expressed as a polyHis-Endostatin fusion protein and purified on Ni2+-NTA beads. The in vitro activity of soluble endostatin was confirmed on bovine capillary endothelial cells and human umbilical vein endothelial cells. The human neuroblastoma cell line SKNAS was injected subcutaneously in the flank of nude mice and administration of the recombinant angiogenesis inhibitor started when tumors reached the size of 100 microm3. Twenty mg/kg of recombinant precipitated endostatin or PBS was subcutaneously injected daily for 12 days. Serum endostatin levels were measured using a competitive enzyme immunoassay. Tumor growth was only slowed down in endostatin-treated mice when compared to control mice, and no statistically significant difference in serum levels of endostatin was observed between endostatin-treated and control groups. The lack of correlation between serum concentration and tumor response raises concern regarding the mechanism of action of endostatin.
authors.affiliation: Département de Biologie des tumeurs, Centre León Bérard, Lyon, France.
authors.forename: E
authors.initials: E
authors.lastname: Jouanneau
authors.forename: L
authors.initials: L
authors.lastname: Alberti
authors.forename: M
authors.initials: M
authors.lastname: Nejjari
authors.forename: I
authors.initials: I
authors.lastname: Treilleux
authors.forename: I
authors.initials: I
authors.lastname: Vilgrain
authors.forename: A
authors.initials: A
authors.lastname: Duc
authors.forename: V
authors.initials: V
authors.lastname: Combaret
authors.forename: M
authors.initials: M
authors.lastname: Favrot
authors.forename: P
authors.initials: P
authors.lastname: Leboulch
authors.forename: T
authors.initials: T
authors.lastname: Bachelot
mesh_terms: D020533:Angiogenesis Inhibitors / Q000235:genetics / Q000302:isolation & purification / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D002417:Cattle; D003094:Collagen / Q000235:genetics / Q000302:isolation & purification / Q000493:pharmacokinetics / Q000627:therapeutic use*; D043169:Endostatins; D004926:Escherichia coli / Q000235:genetics; D015870:Gene Expression; D005798:Genes, Bacterial / Q000502:physiology; D005822:Genetic Vectors; D006801:Humans; D051379:Mice; D009368:Neoplasm Transplantation; D009447:Neuroblastoma / Q000188:drug therapy*; D010446:Peptide Fragments / Q000235:genetics / Q000302:isolation & purification / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D014183:Transplantation, Heterologous; D017211:Treatment Failure
chemical_list: D020533:Angiogenesis Inhibitors; D043169:Endostatins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D003094:Collagen